Trusted by 10,000+ Scientists since 2006


Inhibitory Selectivity
Catalog No.Inhibitor Name Tie-2Other
A10932Tie2 kinase inhibitor
A10895Pexmetinib (ARRY-614)
p38 MAPK
A14387Altiratinib (DCC2701)

1.Hover mouse over " * " to view the IC50 value.(A few compounds have proven potency but without published IC50 data.)
2.For more details about the compound, click on the product name of your interest.
3.The higher the number of " * " is, the more potent the inhibitor or activator is.
4."" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

6 Item(s)

per page

Set Descending Direction
Catalog No. Product Name Application Product Information
A10996 SALE

XL184 free base (Cabozantinib)

VEGFR inhibitor
XL184 free base (Cabozantinib) is a small molecule designed to inhibit multiple receptor tyrosine kinases, specifically MET and VEGFR2.

MGCD-265 (Glesatinib)

c-Met inhibitor
MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs, including the c-Met receptor (HGFR); the Tek/Tie-2 receptor; VEGFR types 1, 2, and 3; and MST1R.

Tie2 kinase inhibitor

Tie2 kinase inhibitor is a potent and selective Tie2 inhibitor with IC50 of 0.25 μM.


Tie-2 inhibitor
AMG-Tie2-1 is a highly potent, non-selective inhibitor of Tie-2 (IC50 <1 nM).

Altiratinib (DCC2701)

c-Met/VEGFR inhibitor
Altiratinib is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumor burden in vivo and block c-MET pTyr(1349)-mediated signaling, cell growth and migration as compared with a HGF antagonist in vitro.

Pexmetinib (ARRY-614)

p38 MAPK inhibitor
Pexmetinib is a potent inhibitor of cytokine synthesis, via the dual inhibition of p38 mitogen-activated protein kinase (MAPK), and Tie2/Tek receptor tyrosine kinase.

6 Item(s)

per page

Set Descending Direction